February 23, 2022
Edited by Christina Ji-Hye Yang; Esther H. Lim; Elizabeth D. Ferrill
In a per curiam order, GlaxoSmithKline LLC v. Teva Pharmaceuticals USA, Inc., Nos. 2018-1976, 2018-2023 (Fed. Cir. Feb. 11, 2022), the Federal Circuit denied Teva’s petition for rehearing en banc of the panel decision, which found Teva’s induced infringement of GSK’s carvedilol patent based on its generic drug label.
The patent-in-suit is directed to a method of treating congestive heart failure with carvedilol. Teva argued against inducement liability, citing its alleged compliance with the FDA-regulated practice of “skinny-labeling” its generic drug, which carved out the patented indication for heart failure based on GSK’s sworn statements. In a 6-3 split decision, the Federal Circuit acknowledged potential fairness concerns in finding Teva liable for inducement despite the skinny label, but ultimately denied review because Teva’s un-adjudicated equitable estoppel defense could lead to the label’s exclusion as inducement evidence. The Court explained that the focus on remand should be Teva’s reasonable reliance on GSK’s communications regarding enforceability of carvedilol’s patented indication, and whether GSK should be equitably estopped from using the skinny label as evidence.
In dissent, Judges Prost, Reyna, and Dyk concluded that Teva adhered to the FDA labelling mandate and its skinny label should not have been used as infringement evidence.
drugs, infringement, estoppel, United States Court of Appeals for the Federal Circuit (CAFC), generic drug
Copyright © 2022 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP.
DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. One of our lawyers will be happy to discuss the possibility of representation with you. Additional disclaimer information.
Conference
Breaking the Concrete Ceiling: How Women of Color Overcome the Invisible Barrier
June 16, 2022
Washington, DC
Webinar
June 14, 2022
Webinar
Webinar
Manufacturing Monetization: Due Diligence Before Licensing or Litigating Your Patent Portfolio
June 8, 2022
Webinar
At the PTAB Blog
May 25, 2022
Due to international data regulations, we’ve recently updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.